Work

A Signal Without an Answer: Ceftriaxone, Anaphylaxis, and the Limits of Public Health Investigation

Year: 2026

Type: article

Source: Clinical Infectious Diseases

DOI: 10.1093/cid/ciag529

Authors: Santiago Alvarez-Arango, Elizabeth J Phillips

Institutions: The University of Texas Southwestern Medical Center, Vanderbilt University Medical Center

Language: English

Topic: Pharmacovigilance and Adverse Drug Reactions

Subfield: Toxicology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Eli Lilly and Company, AstraZeneca, LEO Fondet, Esperion Therapeutics, National Institutes of Health, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, Janssen Biotech

Awards: Stevens-Johnson syndrome/toxic epidermal necrolysis 2021: Collaboration, Innovation and Community, Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors, G9000382585, Immune Tolerance Network, Mechanisms of Immediate Non-IgE-mediated Drug Hypersensitivity Reactions (MIND-HR), Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study), NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

OpenAlex ID: W7206176835

FWCI:

Cites: 16

Cited by:

Related to: 10